For US Healthcare Professionals
HEMLIBRA® (emicizumab-kxwh) Logo Icon

HEMLIBRA is the #1 prescribed prophylaxis for people with hemophilia A without factor VIII inhibitors§

*November 2017: FDA approval for adults and children with hemophilia A with factor VIII inhibitors.
†Number of people with hemophilia A treated with HEMLIBRA worldwide as of June 2025.
‡Number of people with hemophilia A treated with HEMLIBRA in the US as of November 2025.
§According to IQVIA claims data (various insurance plan types) from Jul’24-Jun’25 (Refreshed Sep’25), accounting for prophylaxis use in the US.

HEMLIBRA® (emicizumab-kxwh) Ambassador Group Selfie

Hear From the Community

9 in 10 people are highly satisfied with their HEMLIBRA treatment.II

Say Hello
HEMLIBRA® (emicizumab-kxwh) Ambassador Miles

Move on From Highs and Lows

HEMLIBRA's unique 4-week half-life offers consistent and sustained drug levels.

Learn More
HEMLIBRA® (emicizumab-kxwh) Ambassador Maria and Carlos

Support, Tips, and Tricks

Your guide to a more comfortable injection experience.

Get Tips

IIBased on a blinded survey of 62 people with hemophilia A without inhibitors and their caregivers who were asked about current HEMLIBRA treatment and ranked their satisfaction on a scale of 1: Not at all satisfied to 7: Extremely satisfied. 55 respondents rated HEMLIBRA as 6 or 7. Commissioned by Genentech in September 2023.

HEMLIBRA (emicizumab-kxwh) is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

With a half-life of four weeks, it provides consistent and sustained drug levels between doses and proven bleed protection as demonstrated by clinical trials.

HEMLIBRA acts like a bridge, bringing factor IXa and factor X together to help your blood clot. HEMLIBRA allows the blood coagulation process to continue without needing to replace factor VIII.

HEMLIBRA is administered as a subcutaneous injection given as a shot under the skin (a subcutaneous injection), so you don't need to find a vein to take your dose of HEMLIBRA. It can be taken at home after training from a healthcare provider. After four weeks of weekly loading doses, it offers flexible dosing options, including once weekly, every two weeks, or every four weeks.

People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots, conditions that require immediate medical attention. Common side effects include injection site reactions, headache, and joint pain.

Important Safety Information & Indication

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include: 

  • Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood  vessels that may cause harm to your kidneys, brain, and other organs 
  • Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head  

Talk to your doctor about the signs and symptoms of these serious side effects, which can include: 

  • Confusion
  • Stomach, chest, or back pain
  • Weakness
  • Nausea or vomiting
  • Swelling, pain, or redness
  • Feeling sick or faint
  • Decreased urination
  • Swelling of arms and legs
  • Yellowing of skin and eyes
  • Eye pain, swelling, or trouble seeing
  • Fast heart rate
  • Numbness in your face
  • Headache
  • Shortness of breath
  • Coughing up blood

If you experience any of these symptoms during or after treatment with HEMLIBRA, get medical help right away. 

Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total. 

Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).

The most common side effects of HEMLIBRA include: injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.

What else should I know about HEMLIBRA?

See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

  • Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA
  • You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care. 

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Only use HEMLIBRA for the condition it was prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist.

Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

Since HEMLIBRA was tested in males, there is no information on whether HEMLIBRA may impact your unborn baby or breast milk. Females who are able to become pregnant should use birth control during treatment.

Side effects may be reported to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.